Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Change in Cash (2016 - 2025)

Angiodynamics (ANGO) has disclosed Change in Cash for 16 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash rose 413.97% year-over-year to $2.9 million, compared with a TTM value of -$12.5 million through Nov 2025, down 82.91%, and an annual FY2025 reading of -$20.2 million, down 164.14% over the prior year.
  • Change in Cash was $2.9 million for Q4 2025 at Angiodynamics, up from -$17.1 million in the prior quarter.
  • Across five years, Change in Cash topped out at $17.6 million in Q1 2024 and bottomed at -$21.1 million in Q3 2024.
  • Average Change in Cash over 5 years is -$819350.0, with a median of -$1.0 million recorded in 2021.
  • Peak annual rise in Change in Cash hit 6811.42% in 2024, while the deepest fall reached 262.36% in 2024.
  • Year by year, Change in Cash stood at -$1.2 million in 2021, then soared by 548.18% to $5.3 million in 2022, then plummeted by 37.46% to $3.3 million in 2023, then plummeted by 127.67% to -$916000.0 in 2024, then soared by 413.97% to $2.9 million in 2025.
  • Business Quant data shows Change in Cash for ANGO at $2.9 million in Q4 2025, -$17.1 million in Q3 2025, and $11.1 million in Q2 2025.